Abraxis BioScience (ABBI) Receives Tentative FDA Approval for Granisetron
Abraxis BioScience, Inc. (NASDAQ: ABBI) received tentative approval from the FDA of its Abbreviated New Drug Application for Granisetron Hydrochloride Injection, 1 mg/mL, 1 mL vials, USP, the generic equivalent of Hoffmann-La Roche's Kytril Injection.
You May Also Be Interested In
- Baxter Int'l (BAX) says low-glucose PD regimen has favorable impact on ESRD patients w/ diabetes
- POZEN (POZN) Says PA32540 Gets to Gastric pH Faster than Enteric-Coated Omeprazole
- Bayer, Onyx Pharma (ONXX) Say Nexavar Missed Primary Endpoint in Phase 3
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
